Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Trastuzumab emtansine
État du projet:
Terminé
Domaine thérapeutique:
Advanced or Metastatic Breast Cancer
Fabricant:
Hoffman-La Roche Ltd.
Brand Name:
Kadcyla
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0024-000
Strength:
100mg and 160 mg vial
Tumour Type:
Breast
Indications:
Metastatic Breast Cancer
Funding Request:
The treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Hoffman-La Roche Ltd.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et accordée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
Recommandation:
Remboursement sous critères cliniques ou conditions
Clarification:
A delay in the receipt of marketing authorization (NOC) from Health Canada has impacted the review timeline.
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016